Standard BioTools Exceeds 2025 Revenue Guidance, Anticipates $550M Cash Post-SomaLogic Sale
LAB sits 46% above its 52-week low of $0.92.
Summary
Standard BioTools announced preliminary 2025 revenue exceeding guidance and confirmed the SomaLogic divestiture is on track to yield $550 million in cash, significantly bolstering its financial position.
Key Events · Earnings and Guidance · LAB
-
Preliminary 2025 Revenue Exceeds Guidance
Standard BioTools reported preliminary, unaudited combined company revenue of approximately $185 million for the full year 2025, exceeding its previous guidance range.
-
SomaLogic Divestiture on Track
The sale of SomaLogic to Illumina is progressing as planned and is expected to close in the first half of 2026.
-
Significant Cash Inflow Expected
Upon the closing of the SomaLogic transaction, the company anticipates having approximately $550 million in cash, providing substantial strategic flexibility.
-
Path to Profitability and Strategic M&A
The company is on its way to positive adjusted EBITDA and plans to pursue disciplined mergers and acquisitions to build a diversified leader in life sciences.
Analysis · LAB · Industrial Applications And Services
Standard BioTools Inc. reported preliminary 2025 revenue figures that surpassed its guidance range, indicating strong operational performance. The company's CEO highlighted steady execution and progress towards profitability through streamlined operations and improved cost structure. Crucially, the update confirms the SomaLogic divestiture is on track to close in the first half of 2026, which is expected to provide approximately $550 million in cash. This substantial cash infusion, exceeding the company's current market capitalization, offers significant strategic flexibility for disciplined M&A and future growth initiatives, positioning the company as a more resilient business.
At the time of this filing, LAB was trading at $1.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $492.2M. The 52-week trading range was $0.92 to $2.14. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.